Skip to main content
Top
Published in: BMC Medicine 1/2010

Open Access 01-12-2010 | Commentary

Enhancement drugs: are there limits to what we should enhance and why?

Author: Morten Hesse

Published in: BMC Medicine | Issue 1/2010

Login to get access

Abstract

Substances, such as alcohol, opiates and cannabis, have been used by humans for millennia. Today, a much wider range of substances are used for a range of purposes, including the enhancement of performance during university studies, sexual experiences, sports, exercise, at celebrations, socializing and the experience of art and music. Substance use is also associated with a range of harmful effects to the individual and society as a whole. Prohibitions, regulation, prevention and treatment have all been used to protect against this harm. In this commentary, it is argued that public health interventions should target relevant harms and not to evaluate which aspects of human endeavors and experiences should be enhanced and which should not. It is argued that interventions should directly target the harmful effects, using the best available evidence. Two examples are given of substances that may be altered to prevent serious harm - one for alcohol and one for cannabis. In the case of alcohol, the addition of dissolved oxygen could reduce both the risk of accidents and the risk of liver damage associated with alcohol consumption. In the case of cannabis, there is strong indication that the reduction of content Δ-tetrahydrocannabinol and the increase of cannabidiol could reduce the risk of psychoses and the addiction associated with its use. The aim of this article is to show that responsible regulation should not necessarily be restricted to preventing the use and/or (in the case of alcohol) a reduction in the amounts and frequency of its use, but should also aim to include a range of other strategies that could reduce the burden of illness associated with illicit substance use.
Literature
1.
go back to reference Sutton DF: Ancient Comedy. 1993, New York: Twayne Publishers Sutton DF: Ancient Comedy. 1993, New York: Twayne Publishers
2.
3.
go back to reference Eloi-Stiven ML, Channaveeraiah N, Christos PJ, Finkel M, Reddy R: Does marijuana use play a role in the recreational use of sildenafil?. J Family Practice. 2007, 56: E1-E4. Eloi-Stiven ML, Channaveeraiah N, Christos PJ, Finkel M, Reddy R: Does marijuana use play a role in the recreational use of sildenafil?. J Family Practice. 2007, 56: E1-E4.
4.
go back to reference Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG: Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009, 104: 1966-1978. 10.1111/j.1360-0443.2009.02734.x.CrossRefPubMedPubMedCentral Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG: Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009, 104: 1966-1978. 10.1111/j.1360-0443.2009.02734.x.CrossRefPubMedPubMedCentral
5.
go back to reference Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ: Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008, 456: 702-705. 10.1038/456702a.CrossRefPubMed Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ: Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008, 456: 702-705. 10.1038/456702a.CrossRefPubMed
6.
go back to reference Goldman D, Oroszi G, Ducci F: The genetics of addictions: uncovering the genes. Nature Rev Genetics. 2005, 6: 521-532. 10.1038/nrg1635.CrossRef Goldman D, Oroszi G, Ducci F: The genetics of addictions: uncovering the genes. Nature Rev Genetics. 2005, 6: 521-532. 10.1038/nrg1635.CrossRef
7.
go back to reference Soderstrom CA, Cole FJ, Porter JM: Injury in America: the role of alcohol and other drugs--an EAST Position paper prepared by the Injury Control and Violence Prevention Committee. J Trauma Injury, Infection, Crit Care. 2001, 50: 1-12. 10.1097/00005373-200101000-00001.CrossRef Soderstrom CA, Cole FJ, Porter JM: Injury in America: the role of alcohol and other drugs--an EAST Position paper prepared by the Injury Control and Violence Prevention Committee. J Trauma Injury, Infection, Crit Care. 2001, 50: 1-12. 10.1097/00005373-200101000-00001.CrossRef
8.
go back to reference Morgan CJA, Muetzelfeldt L, Muetzelfeldt M, Nutt DJ, Curran HV: Harms associated with psychoactive substances: findings of the UK National Drug Survey. J Psychopharmacol. 2010, 24: 147-153. 10.1177/0269881109106915.CrossRefPubMed Morgan CJA, Muetzelfeldt L, Muetzelfeldt M, Nutt DJ, Curran HV: Harms associated with psychoactive substances: findings of the UK National Drug Survey. J Psychopharmacol. 2010, 24: 147-153. 10.1177/0269881109106915.CrossRefPubMed
9.
go back to reference Rehm J, Taylor B, Room R: Global burden of disease from alcohol, illicit drugs and tobacco. Drug Alcohol Rev. 2006, 25: 503-513. 10.1080/09595230600944453.CrossRefPubMed Rehm J, Taylor B, Room R: Global burden of disease from alcohol, illicit drugs and tobacco. Drug Alcohol Rev. 2006, 25: 503-513. 10.1080/09595230600944453.CrossRefPubMed
10.
go back to reference Baek IH, Lee BY, Kwon KI: Influence of dissolved oxygen concentration on the pharmacokinetics of alcohol in humans. Alcoholism. Clin Expl Res. 2010, 34: 834-839. 10.1111/j.1530-0277.2010.01155.x.CrossRef Baek IH, Lee BY, Kwon KI: Influence of dissolved oxygen concentration on the pharmacokinetics of alcohol in humans. Alcoholism. Clin Expl Res. 2010, 34: 834-839. 10.1111/j.1530-0277.2010.01155.x.CrossRef
11.
go back to reference Hall W, Degenhardt L: Adverse health effects of non-medical cannabis use. Lancet. 2009, 374: 1383-1391. 10.1016/S0140-6736(09)61037-0.CrossRefPubMed Hall W, Degenhardt L: Adverse health effects of non-medical cannabis use. Lancet. 2009, 374: 1383-1391. 10.1016/S0140-6736(09)61037-0.CrossRefPubMed
12.
go back to reference Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J: Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004, 99: 1333-1341. 10.1111/j.1360-0443.2004.00806.x.CrossRefPubMed Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J: Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004, 99: 1333-1341. 10.1111/j.1360-0443.2004.00806.x.CrossRefPubMed
13.
go back to reference Smit F, Bolier L, Cuijpers P: Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004, 99: 425-430. 10.1111/j.1360-0443.2004.00683.x.CrossRefPubMed Smit F, Bolier L, Cuijpers P: Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004, 99: 425-430. 10.1111/j.1360-0443.2004.00683.x.CrossRefPubMed
14.
go back to reference Lader M: Addiction and the pharmacology of cannabis: implications for medicine and the law. Med Sci Law. 2009, 49: 1-17. 10.1258/rsmmsl.49.1.1.CrossRefPubMed Lader M: Addiction and the pharmacology of cannabis: implications for medicine and the law. Med Sci Law. 2009, 49: 1-17. 10.1258/rsmmsl.49.1.1.CrossRefPubMed
15.
go back to reference Morgan CJA, Curran HV: Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008, 192: 306-307. 10.1192/bjp.bp.107.046649.CrossRefPubMed Morgan CJA, Curran HV: Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008, 192: 306-307. 10.1192/bjp.bp.107.046649.CrossRefPubMed
16.
go back to reference Ross SA, Mehmedic Z, Murphy TP, Elsohly MA: GC-MS analysis of the total delta9-THC content of both drug- and fiber-type cannabis seeds. J Analyt Toxicol. 2000, 24: 715-717.CrossRef Ross SA, Mehmedic Z, Murphy TP, Elsohly MA: GC-MS analysis of the total delta9-THC content of both drug- and fiber-type cannabis seeds. J Analyt Toxicol. 2000, 24: 715-717.CrossRef
17.
go back to reference Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, et al: High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009, 195: 488-491. 10.1192/bjp.bp.109.064220.CrossRefPubMedPubMedCentral Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, et al: High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009, 195: 488-491. 10.1192/bjp.bp.109.064220.CrossRefPubMedPubMedCentral
18.
go back to reference Hall W, Fischer B: Harm reduction policies for cannabis. Harm Reduction: Evidence, Impacts and Challenges. Edited by: Rhodes T, Hedrich D. 2010, Lisbon: EMCDDA [EMCDDA Monographs] Hall W, Fischer B: Harm reduction policies for cannabis. Harm Reduction: Evidence, Impacts and Challenges. Edited by: Rhodes T, Hedrich D. 2010, Lisbon: EMCDDA [EMCDDA Monographs]
Metadata
Title
Enhancement drugs: are there limits to what we should enhance and why?
Author
Morten Hesse
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2010
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-8-50

Other articles of this Issue 1/2010

BMC Medicine 1/2010 Go to the issue